AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MCDS | 67.41 | -0.03 | -0.04% |
| JPMorgan Fundamental Data Science Mid Core ETF (MCDS) | |||
| JMTG | 48.65 | -0.03 | -0.06% |
| JPMorgan Mortgage-Backed Securities ETF (JMTG) | |||
| MAXJ | 29.51 | -0.04 | -0.12% |
| iShares Large Cap Max Buffer Jun ETF (MAXJ) | |||
| PIZ | 49.53 | -0.12 | -0.24% |
| Invesco Dorsey Wright Developed Markets Momentum ETF (PIZ) | |||
| FLAO | 28.62 | -0.07 | -0.24% |
| AllianzIM U.S. Equity 6 Month Floor5 Apr/Oct ETF (FLAO) | |||
A.I.dvisor indicates that over the last year, ACIU has been loosely correlated with SANA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ACIU jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To ACIU | 1D Price Change % | ||
|---|---|---|---|---|
| ACIU | 100% | -0.47% | ||
| SANA - ACIU | 43% Loosely correlated | +0.50% | ||
| EDIT - ACIU | 42% Loosely correlated | +1.40% | ||
| KYTX - ACIU | 42% Loosely correlated | +0.40% | ||
| ALEC - ACIU | 41% Loosely correlated | +3.67% | ||
| BEAM - ACIU | 41% Loosely correlated | -4.99% | ||
More | ||||
a developer of therapeutic and diagnostic products to prevent and modify diseases caused by misfolding proteins
Industry Biotechnology
The Moving Average Convergence Divergence (MACD) for ACIU turned positive on November 09, 2026. Looking at past instances where ACIU's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACIU's RSI Indicator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 68 cases where ACIU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +15.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACIU advanced for three days, in 164 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ACIU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACIU as a result. In 75 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 10-day moving average for ACIU crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACIU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ACIU entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.304) is normal, around the industry mean (3.498). P/E Ratio (-5.186) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.547) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. ACIU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACIU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.